Company Participants Reshma Kewalramani - President & Chief Executive Officer Charlie Wagner - Executive Vice President & Chief Financial Officer Salveen Richter - Goldman Sachs Mohit Bansal - Wells Fargo Robyn Karnauskas - Truist Securities Chris Raymond - Piper Sandler Operator Susie Lisa We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today's press release and in our filings with the Securities and Exchange Commission. These stat ...

FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ©2024 Vertex Pharmaceuticals Incorporated VERTEX FEBRUARY 5, 2024 AGENDA Introduction Susie Lisa, CFA, Senior Vice President, Investor Relations CEO Perspective and Pipeline Update Reshma Kewalramani, M.D., Chief Executive Officer and President Commercial Update Stuart Arbuckle, Executive Vice President and Chief Operating Officer Financial Results Charlie Wagner, Executive Vice President and Chief Financial Officer ©2024 Vertex Pharmaceuticals Incorporate ...

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.20 per share, beating the Zacks Consensus Estimate of $4.10 per share. This compares to earnings of $3.76 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.44%. A quarter ago, it was expected that this drugmaker would post earnings of $3.92 per share when it actually produced earnings of $4.08, delivering a surprise of 4.08%.Over the last four quarters, the c ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its once-daily vanzacaftor/tezacaftor/deutivacaftor (the “vanza triple”) program, the most comprehensive Phase 3 pivotal program ever conducted by Vertex for the treatment of cystic fibrosis (CF), a progressive, multi-organ disease caused by dysfunction of the CFTR protein. The Phase 3 program included two randomized, double-blind, active-controlled, 52-week trials, SKYLINE 102 and SKYLINE 103, ...

Vertex Pharmaceuticals (VRTX -2.12%) already brings in billions of dollars annually, thanks to its cystic fibrosis (CF) drugs. The company recently proved it could expand beyond the specialty area when it won approval with partner CRISPR Therapeutics for a gene editing therapy for blood disorders.Next, Vertex is about to show that it can conquer one of the world's most common health problems: pain. The company recently reported positive phase 3 data for VX-548, its treatment candidate for moderate-to-severe ...

Vertex Pharmaceuticals (VRTX) announced positive results from three late-stage studies on its investigational orally-administered non-opioid pain medicine, VX-548, to treat moderate-to-severe acute pain.The company evaluated VX-548, a novel first-in-class NaV1.8 inhibitor, in two pivotal phase III acute pain studies — one following bunionectomy surgery and the other following abdominoplasty surgery. The studies achieved their primary endpoint — treatment with VX-548 showed a significant reduction in pain in ...

The upcoming report from Vertex Pharmaceuticals (VRTX) is expected to reveal quarterly earnings of $4.08 per share, indicating an increase of 8.5% compared to the year-ago period. Analysts forecast revenues of $2.5 billion, representing an increase of 8.5% year over year.The consensus EPS estimate for the quarter has undergone an upward revision of 0.4% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during ...

Good news from the lab sparked a mini-rally in Vertex Pharmaceuticals (VRTX 2.35%) stock on Tuesday. The biotech's shares closed the trading session more than 2% higher in price, which was good enough to top the flat-lining S&P 500 index. One of the company's investigational drugs is showing decent promise in a clinical trial.Pain drug meets primary endpoint in studyVertex announced that its VX-548, a non-opioid medication aimed at treating moderate to severe acute pain, met its primary endpoint in a phase ...

A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston on Oct. 23, 2019.Vertex Pharmaceuticals on Tuesday said its experimental painkiller, which is being tested as an alternative to addictive opioids, significantly decreased post-surgery pain in late-stage trialsThe drug, known as VX-548, did not work better than a popular opioid, however.Still, the trial results bring the biotech company one step closer to developing a drug that can provide strong pain relief without the addic ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 3 program for the selective NaV1.8 inhibitor, VX-548, in the treatment of moderate-to-severe acute pain. The Phase 3 program included two randomized, double-blind, placebo-controlled, pivotal trials, one following abdominoplasty surgery and one following bunionectomy surgery, as well as a single arm safety and effectiveness study which enrolled patients with a broad range of surgical a ...